This NDC is on FDA's drug shortage list (posted Jul 14, 2023)
Product Information
VYVANSE 50 MG CAPSULE is a brand product labeled by Takeda Pharmaceuticals America, Inc., priced at $12.3472 per EA under NDC 59417010510. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Feb 23, 2007. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the lisdexamfetamine dimesylate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
50 mg/1
Manufacturer
Takeda Pharmaceuticals America, Inc.NDC
59417010510
Classification
Brand
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LISDEXAMFETAMINE DIMESYLATEApproval Type
New Drug (NDA)
FDA Application
NDA021977FDA Approved
2/23/2007
TE Code
AB
On Market Since
2/23/2007
Pharmacological Classes
Price Statistics
The NADAC for VYVANSE 50 MG CAPSULE has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 109.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $12.3472 per EA |
|---|---|
| All-time high | $12.4029 (Sep 11, 2024) |
| All-time low | $5.9080 (Nov 28, 2013) |
| 52-week high | $12.3733 |
| 52-week low | $12.3472 |
| Median price | $10.1926 |
| Average price | $9.9503 |
| Largest weekly change | +9.0% (Jan 13, 2016) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 79% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Takeda Pharmaceuticals America, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
lisdexamfetamine dimesylate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central Nervous System Stimulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VYVANSE 50 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for VYVANSE 50 MG CAPSULE, manufactured by Takeda Pharmaceuticals America, Inc., is $12.3472 per EA (NDC 59417010510), effective Sep 30, 2026.
How has the price of VYVANSE 50 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for VYVANSE 50 MG CAPSULE has risen 109.0%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for VYVANSE 50 MG CAPSULE?
Since Nov 28, 2013, the NADAC for VYVANSE 50 MG CAPSULE has ranged from a low of $5.9080 (Nov 28, 2013) to a high of $12.4029 (Sep 11, 2024), with a median of $10.1926 per EA.
Are there cheaper alternatives to VYVANSE 50 MG CAPSULE?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LISDEXAMFETAMINE 50 MG CAPSULE, is $2.6398 per EA — about 79% below VYVANSE 50 MG CAPSULE.
Who manufactures VYVANSE 50 MG CAPSULE?
VYVANSE 50 MG CAPSULE (NDC 59417010510) is labeled by Takeda Pharmaceuticals America, Inc., and CMS classifies it as a brand product.
Is VYVANSE 50 MG CAPSULE in shortage?
Yes — NDC 59417010510 is currently listed in FDA's drug shortage database (posted Jul 14, 2023).